Vallittu A M, Salmi A A, Erälinna J P
Department of Virology, University of Turku, Finland.
Neurol Sci. 2006 Feb;26(6):438-43. doi: 10.1007/s10072-006-0529-7.
MxA protein production in peripheral blood leukocytes is a valuable marker to evaluate biologic effects of interferon-beta (IFNbeta) therapy in multiple sclerosis (MS) patients. The three IFNbeta preparations available in the treatment of MS differ with respect to antigenicity and biologic activity. We studied prospectively the induction of MxA protein and the development of binding (BAb) and neutralising antibodies (NAb) in nine relapsing-remitting MS (RRMS) patients during one year of intramuscular IFNbeta -1a (Avonex) treatment. Another nine RRMS patient treated with Avonex for 1-3.5 years were also included. The results were compared with our earlier published data of subcutaneous IFNbeta-1a (Rebif). None of these 18 patients developed NAb but three of the long-term patients developed BAb. The baseline MxA protein levels rose but the induction was weaker compared to Rebif. The stimulation index (MxA after/before IFNbeta-1a injection) remained elevated. Weekly intramuscular dosing of IFNbeta-1a provides a sustained effect on lymphocytes but differences in leukocyte stimulation may underlie some of the differences between IFNbeta therapies.
外周血白细胞中Mx A蛋白的产生是评估干扰素-β（IFNβ）治疗对多发性硬化症（MS）患者生物学效应的一个重要指标。目前用于治疗MS的三种IFNβ制剂在抗原性和生物学活性方面存在差异。我们前瞻性地研究了9例复发缓解型MS（RRMS）患者在接受肌肉注射IFNβ-1a（Avonex）治疗一年期间Mx A蛋白的诱导情况以及结合抗体（BAb）和中和抗体（NAb）的产生情况。另外还纳入了9例接受Avonex治疗1 - 3.5年的RRMS患者。将结果与我们之前发表的皮下注射IFNβ-1a（Rebif）的数据进行比较。这18例患者中无一例产生NAb，但有3例长期患者产生了BAb。基线Mx A蛋白水平升高，但与Rebif相比诱导作用较弱。刺激指数（IFNβ-1a注射后/注射前的Mx A）仍保持升高。每周一次肌肉注射IFNβ-1a对淋巴细胞有持续作用，但白细胞刺激的差异可能是IFNβ疗法之间某些差异的原因。
